Cingulate Inc. (NASDAQ:CINGW) Sees Significant Decline in Short Interest

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 8,032 shares, a decrease of 42.1% from the January 15th total of 13,862 shares. Based on an average daily volume of 52,919 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 52,919 shares, the days-to-cover ratio is currently 0.2 days.

Cingulate Stock Performance

NASDAQ:CINGW opened at $0.04 on Friday. The business has a 50 day moving average of $0.07 and a 200 day moving average of $0.06. Cingulate has a 1-year low of $0.02 and a 1-year high of $0.18.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.